Mark A. Socinski

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations

Medicine, Genetics, Oncology +17

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Vera Hirsh, Tony Mok et al. · The Lancet · 2008 · 1.2K citations

Medicine, Oncology, Pharmacology +8

Weekly <i>nab</i>-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Mark A. Socinski, Igor Bondarenko, Nina Karaseva et al. · Journal of Clinical Oncology · 2012 · 754 citations · Full text

Medicine, Oncology, Pharmacology +14

Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression

Karen Antman, James D. Griffin, Anthony Elias et al. · New England Journal of Medicine · 1988 · 684 citations

Medicine, Hematology, Oncology +17